Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

被引：0

作者：

Vitale, Nuzzo Pier

Pond, Gregory Russell

Abou Alaiwi, Sarah

Nassar, Amin

Flippot, Ronan

Choueiri, Toni K.

Harshman, Lauren Christine

Sonpavde, Guru

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[4] Hop Piti Salpetriere, Lab Avec Fdn, Paris, France

[5] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA

[6] Harvard Med Sch, Boston, MA 02115 USA

[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16038

引用

页数：1